Patrick Hwu: Insights into CAR design and optimal coupling to inhibit the PD-L1/PD-1 axis

Patrick Hwu shared on X/Twitter:

“Science Saturday

T-cells gene-modified with chimeric antigen receptors (CAR) can be inhibited by the PD-L1 molecule on tumor and stromal cells. How does CAR design impact T-cell inhibition by PD-L1? In this study, Sonia Guedan evaluated the role of CAR affinity and co-stimulatory domains on T-cell susceptibility to PD-L1 mediated suppression. The team found that low affinity CAR-T cells with CD28 or ICOS but not 4-1BB co-stimulatory domains were most susceptible to PD-L1 suppression. This study lends insights into CAR design and optimal coupling with strategies to inhibit the PD-L1/PD-1 axis.

Here’s a link to the full article.”

Source: Patrick Hwu/X

Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy. He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.

Before joining, Dr. Hwu held numerous leadership roles at The University of Texas MD Anderson Cancer Center for over 17 years. Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research. Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.